Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 382,020,224
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,034 M
  • EBITDA $ 17,420 M
  • 60-Month Beta 0.36
  • Price/Sales 6.43
  • Price/Cash Flow 14.35
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 29.47% (-0.13%)
  • Historical Volatility 25.61%
  • IV Percentile 84%
  • IV Rank 35.08%
  • IV High 51.27% on 04/08/25
  • IV Low 17.68% on 02/19/25
  • Expected Move (DTE 1) 3.11 (1.44%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 13,379
  • Volume Avg (30-Day) 53,553
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 198,793
  • Open Int (30-Day) 271,876
  • Expected Range 213.04 to 219.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.82
  • Number of Estimates 4
  • High Estimate 3.34
  • Low Estimate 2.62
  • Prior Year 2.16
  • Growth Rate Est. (year over year) +30.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
209.96 +2.95%
on 01/20/26
237.04 -8.81%
on 01/07/26
-10.67 (-4.70%)
since 12/19/25
3-Month
209.96 +2.95%
on 01/20/26
239.29 -9.67%
on 11/13/25
-15.24 (-6.59%)
since 10/21/25
52-Week
164.39 +31.49%
on 04/09/25
244.81 -11.71%
on 10/01/25
+43.54 (+25.22%)
since 01/21/25

Most Recent Stories

More News
1 Safe-and-Steady Stock on Our Watchlist and 2 We Find Risky

1 Safe-and-Steady Stock on Our Watchlist and 2 We Find Risky

MCY : 88.60 (-0.81%)
STC : 66.31 (+1.98%)
ABBV : 216.15 (+0.99%)
The 3 Most Reliable Dividend Stocks to Buy for Years to Come

These three dividend stocks are long-term winners with dependable payouts.

PEP : 146.74 (-0.62%)
ABBV : 216.15 (+0.99%)
O : 61.79 (+0.28%)
3 “Forever Stocks” to Hold When the Market Won’t Sit Still

Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy

CVX : 166.73 (+0.87%)
MRK : 111.11 (+1.52%)
CL : 84.73 (-0.83%)
ABBV : 216.15 (+0.99%)
AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.

ABBV : 216.15 (+0.99%)
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NORTH CHICAGO, Ill. , Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE ® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific...

ABBV : 216.15 (+0.99%)
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

NORTH CHICAGO, Ill. , Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans...

ABBV : 216.15 (+0.99%)
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

-       RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers

ABBV : 216.15 (+0.99%)
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

EXTON, Pa. , Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company...

WST : 255.16 (+1.86%)
ABBV : 216.15 (+0.99%)
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

NORTH CHICAGO, Ill. , Jan. 12, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing...

WST : 255.16 (+1.86%)
ABBV : 216.15 (+0.99%)
This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

CVS : 81.49 (+1.75%)
VHT : 294.37 (+1.73%)
NVO : 59.32 (-2.24%)
JNJ : 218.01 (-0.09%)
MRK : 111.11 (+1.52%)
HCA : 465.44 (+0.23%)
ABBV : 216.15 (+0.99%)
UNH : 347.75 (+2.75%)
ELV : 369.88 (+0.77%)
PFE : 25.89 (+1.45%)
TSLA : 431.44 (+2.91%)
LLY : 1,078.52 (+3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 225.34
2nd Resistance Point 221.67
1st Resistance Point 218.91
Last Price 216.15
1st Support Level 212.48
2nd Support Level 208.81
3rd Support Level 206.05

See More

52-Week High 244.81
Last Price 216.15
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar